“…1,2 Despite its promising efficacy, adverse effects include significant cytokine release syndrome, neurotoxicity, febrile neutropenia, and rarely pneumatosis intestinalis (PI). [3][4][5] PI may be a benign finding that is incidentally identified as the presence of air in the subserosal or submucosal layer of the intestine, but can be a sign of serious conditions, such as bowel ischemia and perforation, and may require surgery. 6,7 To date, only a few patients have developed PI after receiving molecular targeted therapy, but these reports involved bevacizumab, sunitinib, and gefitinib therapy in adult patients.…”